Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.

Health technology assessment (Winchester, England)

Volumn 13 Suppl 3, Issue , 2009, Pages 37-42

  Stevenson, M ^a   Pandor, A ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; FEBUXOSTAT; THIAZOLE DERIVATIVE;

BLOOD; COST BENEFIT ANALYSIS; ECONOMICS; GOUT; HUMAN; HYPERURICEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ALLOPURINOL; COST-BENEFIT ANALYSIS; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLES;

MLCS; MLOWN;

EID: 84891683132     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta13suppl3/06     Document Type: Review

References (8)